611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study

• Robert W Hoffman,
• Robert Gordon,
• Federico Zazzetti,
• Terence Rooney,
• Anne M Stevens,
• Jocelyn H Leu,
• Sheng Gao,
• Qing Zuraw,
• Fang Liu-Walsh,
• Bart van Hartingsveldt,
• Cesar Calderon,
• George Vratsanos

Affiliations

Robert W Hoffman

Eli Lilly and Company, Indianapolis, Indiana, USA

Robert Gordon

Addenbrooke’s Hospital, Cambridge, UK

Federico Zazzetti

Immunology Medical Affairs, Janssen Latin America LLC, Buenos Aires, Argentina

Terence Rooney

3Eli Lilly and Company, Indianapolis, Indiana, USA

Anne M Stevens

Division of Rheumatology, Department of Pediatrics, University of Washington, and Center for Immunity and Immunotherapies, Seattle Children`s Research Institute, Seattle, Washington, USA

Jocelyn H Leu

8Biologics Clinical Pharmacology, Janssen Research & Development, LLC., Spring House, Pennsylvania, USA

Sheng Gao

8 Translational Sciences and Medicine, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA

Qing Zuraw

Immunology Clinical Development, Janssen Research & Development LLC, Spring House, Pennsylvania, USA

Fang Liu-Walsh

1Janssen Research and Development, LLC, Spring House, PA, USA

Bart van Hartingsveldt

2Janssen Biologics Europe, Leiden, the Netherlands

Cesar Calderon

1Janssen Research and Development, LLC, Spring House, PA, USA

George Vratsanos

1Janssen Research and Development, LLC, Spring House, PA, USA